B. Riley significantly reduced its price target for Cue Biopharma from $83 to $25, a substantial downward revision. Despite this, the firm maintained a 'Buy' rating, indicating a belief in long-term potential despite near-term concerns likely stemming from recent Q3 2026 financial results.
B. Riley's drastic reduction of Cue Biopharma's price target from $83 to $25, despite maintaining a 'Buy' rating, signals a significant re-evaluation of the company's near-term prospects. This move likely stems from the recently reported third-quarter 2026 financial results, which may have fallen short of analyst expectations or revealed new challenges. While the 'Buy' rating suggests a belief in long-term value, the short-term implication for traders is likely negative sentiment and potential stock price pressure due to the lowered valuation. This creates a risk for current shareholders and a potential opportunity for short-sellers or those looking for a long-term entry point if the market overreacts.